中文名稱: 決奈達(dá)隆雜質(zhì),艾曲波帕雜質(zhì)對照品
英文名稱:
規(guī)格:10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途:實驗研發(fā),藥品申報檢測,不得用于臨床醫(yī)學(xué)診斷。
隨貨提供:所有雜質(zhì)對照品均隨貨提供HPLC,NMR,MS圖譜及CoA證書。
保存及取用:為了防止產(chǎn)品含量降低,應(yīng)防潮,避光和抗氧化包裝,保存應(yīng)以提高物質(zhì)穩(wěn)定性為原則。如果一次使用很少量,可以將其適當(dāng)分裝后使用,這樣可以有效的防止試劑污染。請不要在臟亂和強光環(huán)境中取用,以免造成污染和失效。
決奈達(dá)隆雜質(zhì),艾曲波帕雜質(zhì)對照品 雜質(zhì)列表:
Dronedarone | N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)methanesulfonamide |
Dronedarone Impurity 1 | N-(3-(4-(3-aminopropoxy)benzoyl)-2-butylbenzofuran-5-yl)methanesulfonamide hydrochloride |
Dronedarone Impurity 2 | N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)formamide hydrochloride |
Dronedarone Impurity 3 | N-butyl-N-(3-(4-(2-butyl-5-(methylsulfonamido)benzofuran-3-carbonyl)phenoxy)propyl)butan-1-amine oxide |
Dronedarone Impurity 4 | N-[2-Butyl-3-[4-[3-(butylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide hydrochloride |
Dronedarone Impurity 5 | (5-amino-2-butylbenzofuran-3-yl)(4-(3-(dibutylamino)propoxy)phenyl)methanone methanone dioxalate |
Dronedarone Impurity 6 | (5-amino-2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone |
Dronedarone Impurity 7 | (2-butyl-5-nitrobenzofuran-3-yl)(4-hydroxyphenyl)methanone |
Dronedarone Impurity 8 | N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide hydrochloride |
Dronedarone Impurity 9 | (2-butyl-5-nitrobenzofuran-3-yl)(4-methoxyphenyl)methanone |
Dronedarone Impurity 10 | (5-amino-2-butylbenzofuran-3-yl)(4-(3-aminopropoxy)phenyl)methanone |
Dronedarone Impurity 11 | (2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)benzofuran-5-yl)sulfamoyl chloride hydrochloride |
Dronedarone Impurity 12 | N,N'-(3,3'-(4,4'-(propane-1,3-diylbis(oxy))bis(benzoyl))bis(2-butylbenzofuran-5,3-diyl))dimethanesulfonamide |
Dronedarone Impurity 13 | Methyl 2-(2-forMyl-4-nitrophenoxy)hexanoate |
Dronedarone Impurity 14 | 2-(2-forMyl-4-nitrophenoxy)hexanoic acid |
Eltrombopag | (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 1 | 5'-chloro-2'-hydroxy-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 2 | 3'-amino-5'-chloro-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 3 | 3'-amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 4 | 1-(3,4-dimethylphenyl)-3-methyl-1H-pyrazol-5(4H)-one |
Eltrombopag Impurity 5 | 1-(3,4-dimethylphenyl)-4-(hydroxyamino)-3-methyl-1H-pyrazol-5(4H)-one |
Eltrombopag Impurity 6 | (E)-1-(3,4-dimethylphenyl)-4-(hydroxyimino)-3-methyl-1H-pyrazol-5(4H)-one |
Eltrombopag Impurity 7 | (Z)-5'-chloro-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 8 | 5',5''-bis((Z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-4'',6'-dihydroxy-[1,1':3',1'':3'',1'''-quaterphenyl]-3,3'''-dicarboxylic acid |
Eltrombopag Impurity 9 | (Z)-ethyl 3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate |
Eltrombopag Impurity 10 | 1',2-bis(3,4-dimethylphenyl)-3-hydroxy-3',5-dimethyl-3,4-dihydro-1'H,2H-[3,4'-bipyrazol]-5'(4'H)-one |
Eltrombopag Impurity 11 | (2R,3R,4R,5S,6R)-6-((3'-((Z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1-hydroxyhydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid |
Eltrombopag Impurity 12 | 3'-acetamido-2'-(((3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 13 | (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxamide |
Eltrombopag Impurity 14 | (Z)-methyl 3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate |
Eltrombopag Impurity 15 | (E)-5'-chloro-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)-1-hydroxyhydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
Eltrombopag Impurity 16 | 1-(4-ethoxyphenyl)-5-(2-hydroxy-4-methoxybenzoyl)pyridin-2(1H)-one |
Eltrombopag Impurity 17 | (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-methoxy-[1,1'-biphenyl]-3-carboxylic acid |
決奈達(dá)隆雜質(zhì),艾曲波帕雜質(zhì)對照品 訂購方式:
聯(lián)系人:何先生
手機:15012456311
QQ:781007885
郵箱:phastandards@gmail.com
歡迎您通過電話,電郵或在線客服向我司詢價及訂購產(chǎn)品。
決奈達(dá)隆雜質(zhì),艾曲波帕雜質(zhì)對照品 作用機理:
日前,美國 FDA 批準(zhǔn)葛蘭素史克艾曲波帕 (Eltrombopag) 補充新藥申請(sNDA),用于對免疫抑制療法(IST) 沒有充分響應(yīng)的嚴(yán)重型再生障礙性貧血 (SAA) 患者治療。艾曲波帕是一種促血小板生成素 (TPO) 受體激動劑,為了增加血細(xì)胞的產(chǎn)生,日服一次艾曲波帕?xí)椭T導(dǎo)骨髓干細(xì)胞的增殖和分化。
決奈達(dá)隆雜質(zhì),艾曲波帕雜質(zhì)對照品 深圳遠(yuǎn)揚專注醫(yī)藥標(biāo)準(zhǔn)品,雜質(zhì)對照品,更多產(chǎn)品,歡迎選購(篇幅有限,只列舉了一小部分,更多更全,請來電詳詢):
雜質(zhì)對照品部分產(chǎn)品列表:
多西他賽雜質(zhì),阿司咪唑雜質(zhì),硝呋太爾雜質(zhì),孟魯司特鈉雜質(zhì),埃博霉素B雜質(zhì),魯比前列酮雜質(zhì),利伐普坦雜質(zhì),卡非佐米雜質(zhì),夫西地酸雜質(zhì),異舒普林雜質(zhì),安塞曲匹雜質(zhì),阿哌沙班雜質(zhì),左西替利嗪雜質(zhì),頭孢噻肟雜質(zhì),西地那非雜質(zhì),哌拉西林雜質(zhì),氟哌利多雜質(zhì),帕唑帕尼雜質(zhì),坎格瑞洛雜質(zhì),阿達(dá)帕林雜質(zhì),阿塞那平雜質(zhì),羅庫溴銨雜質(zhì),匹杉瓊雜質(zhì),夫羅曲坦雜質(zhì),阿戈美拉汀雜質(zhì),普蘆卡必利雜質(zhì),魯格列凈雜質(zhì),克拉霉素雜質(zhì),吡嗪酰胺雜質(zhì),非洛地平雜質(zhì),青蒿琥酯雜質(zhì),鹽酸多佐胺雜質(zhì),替諾福韋酯雜質(zhì),吉法酯雜質(zhì),依佐加濱雜質(zhì),普瑞巴林雜質(zhì),咪達(dá)那新雜質(zhì),瑞格列奈雜質(zhì),米氮平雜質(zhì),潑尼松龍雜質(zhì),氟馬西尼雜質(zhì),馬尼地平雜質(zhì),溴芬酸鈉雜質(zhì),達(dá)巴萬星雜質(zhì),泮托拉唑雜質(zhì),奧美拉唑雜質(zhì),地塞米松雜質(zhì),利奈唑胺雜質(zhì),比卡魯胺雜質(zhì),頭孢克洛雜質(zhì),美洛昔康雜質(zhì),樂卡地平雜質(zhì),氯馬斯汀雜質(zhì),西地那非雜質(zhì),鹽酸瑞伐拉贊雜質(zhì),沙芬酰胺雜質(zhì),阿托伐他汀雜質(zhì),替莫唑胺雜質(zhì),沙格列汀雜質(zhì)